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portantly, both ANP and BNP proved to be very useful forDiagnostic potential of cardiac natriuretic peptides in dialysis
excluding this alteration (negative predictive value 97 and 96%,patients.
respectively). An analysis based on the “best cut-offs” of eachBackground. In the general population, the plasma concen-
peptide as identified on the basis of the ROC curves augmentedtrations of atrial natriuretic peptide (ANP) and brain natri-
the positive and negative prediction values of BNP for theuretic peptide (BNP) are useful to predict left ventricular hy-
diagnosis of LVH to 95 and 61%, respectively. This approachpertrophy (LVH) and LV systolic dysfunction. Whether these
also raised the BNP-positive prediction value for the identifi-cardiac hormones have a similar diagnostic potential in dialysis
cation of LV dysfunction to 31% but did not modify the diag-patients is unknown.
nostic potential of ANP (either for LVH or for LV dysfunction).Methods. We studied the diagnostic value of ANP and BNP
Conclusions. Measuring the plasma concentration of cardiacfor alterations in LV mass and function in a cohort of 246
dialysis patients without clinical evidence of heart failure. natriuretic hormones, particularly BNP, may be useful for the
Results. Both ANP and BNP were independently related to identification of dialysis patients with LVH or for excluding
left ventricular mass (P , 0.0001) as well as to ejection fraction systolic dysfunction.
(P , 0.0001). In an analysis based on a prospectively defined
threshold (95th percentile of the normal range), BNP had a
significantly higher (P , 0.01) sensitivity (88%) than ANP
The observations that the synthesis of atrial and ven-(51%) for the diagnosis of LVH, but the positive predictive
tricular natriuretic peptides is enhanced in the presencevalue of the two peptides was very similar (92 and 87%, respec-
tively, P 5 NS). However, the negative predictive value of of alterations in left ventricular (LV) mass and function,
BNP for excluding LVH was 22% higher than that of ANP and that this phenomenon reliably reflects the severity
(53 vs. 31%, P 5 0.05). Both natriuretic peptides had a high
of left ventricular hypertrophy (LVH) and systolic dys-sensitivity for the detection of LV dysfunction (87 and 94%),
function have focused much attention on the potentialbut their positive predictive value was low (25 and 15%). Im-
diagnostic value of atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) in clinical practice [1–6].
1 The Cardiovascular Risk Extended Evaluation (CREED) investiga-
ANP is released by atrial myocytes in response to stretchtors (institutions) also include Grazia Bonanno, Pasquale Fatuzzo,
Francesco Rapisarda (Divisione Clinicizzata di Nefrologia Chirurgica, associated with increased atrial pressure, while ventricu-
Universita` di Catania); Giuseppe Enia, Vincenzo Panuccio, Maurizio lar production and release of this peptide are triggered
Postorino, Maurizio Garozzo, Carmen Marino, Rocco Tripepi (CNR
only in the presence of ventricular hypertrophy [7]. BNPCentro Fisiologia Clinica, Reggio Cal ); Giuseppe Seminara (Istituto di
Medicina Interna e Geriatria, Universita` di Catania), Emilio Cottini is primarily produced by ventricular myocytes [8], and
(Istituto di Clinica Medica, Universita` di Catania); Vincenzo Candela, its generation rate is amplified by heart failure or LVH
Carlo Labate (Servizio Dialisi, Ospedale “Tiberio Evoli,” Melito Porto
[8–10]. Several studies have examined the utility of natri-Salvo); Filippo Tassone (Servizio di Cardiologia, Ospedale Morelli,
Reggio Cal). uretic peptides for the detection of systolic dysfunction
or LVH in the general population. Whether or not these
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observations hold true in patients with end-stage renalatrial natriuretic peptide, brain natriuretic peptide, left ventricular
hypertrophy, end-stage renal disease. diseases has not been studied. The issue is relevant be-
cause cardiovascular risk in uremic patients on chronicReceived for publication August 15, 2000
dialysis treatment is exceedingly high, and LVH andand in revised form October 18, 2000
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of properly identifying alterations in cardiac mass and Laboratory measurements
function in uremic patients on chronic dialysis treatment, Blood sampling was performed between 8 and 10 a.m.
we prospectively tested the diagnostic potential of ANP during a nondialysis day or with an empty abdomen in
and BNP for LVH and LV dysfunction. CAPD patients. After 20 to 30 minutes of quiet resting in
semirecumbent position, samples were taken into chilled
ethylenediaminetetraacetic acid (EDTA) vacutainers,METHODS
placed immediately on ice, and centrifuged within 30Protocol
minutes at 248C, and the plasma was stored at 2808C
The protocol conformed to the ethical guidelines of before assay. The plasma concentrations of a-human
our institutions, and informed consent was obtained from ANP and BNP were measured by commercially available
each participant. All studies were performed during a radioimmunoassay kits (Peninsula Laboratory Europe
nondialysis day between 8 a.m. and 1 p.m. Ltd., St. Helens, Merseyside, UK) after pre-extraction
by reverse chromatography (Seppak C-18 cartridges;Patients
Waters, Mildford, MA, USA). Recovery was .80% for
Two hundred forty-six patients with end-stage renal both ANP and BNP. There was no cross-reactivity be-
disease (137 males and 109 females) who had been on tween the two assays. The between-assay and within-
regular dialysis treatment [212 on hemodialysis (HD) assay coefficients of variability were 8 and 10% for ANP
and 34 on continuous ambulatory peritoneal dialysis and 9 and 11% for BNP, respectively.
(CAPD)] for at least six months and without clinical Atrial natriuretic peptide and BNP were also mea-
evidence of heart failure or hemodynamically significant sured in 39 control subjects. These subjects were accu-
valvular heart disease were eligible for the study. Heart rately screened to exclude cardiac or other systemic dis-
failure was defined as ejection fraction (EF) of ,35% ease. For the purpose of this study, an elevated value
and dyspnea associated with two of the following condi- was prospectively defined as greater than the 95th per-
tions: raised jugular pressure, bibasilar crackles, pulmo- centile of the normal range (ANP, 27 pmol/L; BNP,
nary venous hypertension, or interstitial edema on chest 7.8 pmol/L).
x-ray, requiring hospitalization or extra ultrafiltration
[12]. All participants were in sinus rhythm at the time Echocardiography
of the study. These patients represented approximately
Echocardiographic measurements were carried out ac-70% of the entire dialysis population of the four dialysis
cording to the recommendations of the American Soci-units. The prevalence of diabetes mellitus in this cohort
ety of Echocardiography [13] always within three hourswas 15% (that is, 37 patients out of 246). Patients ex-
after blood sampling. Left ventricular mass (LVM) wascluded from this study had overt heart failure or valvular
calculated according to the Devereux formula [14] andheart disease, dementia, or terminal diseases or were
indexed to height2.7 (LVMI) [15]. LVH was defined byhospitalized for intercurrent illnesses. No eligible patient
a LVMI of over 47 g/m2.7 in women or over 50 g/m2.7 inrefused to participate into the study. One hundred thirty
men. The height-based indexing of LV mass was specifi-patients were on treatment with erythropoietin. One hun-
cally chosen to minimize any potential distortion attrib-dred nine patients were on antihypertensive treatment:
utable to extracellular volume expansion (surface area76 on monotherapy with angiotensin-converting enzyme
indexing being weight sensitive). Systolic dysfunction(ACE) inhibitors, angiotensin II type 1 (AT1) antago-
was defined as an EF ,45%.nists, calcium channel blockers, a and b blockers, and
33 on double or triple therapy with various combinations
Statistical analysisof these drugs.
Values are expressed as mean 6 SD. The associationAll HD patients were virtually anuric (24-hour urine
of each peptide with physiological variables was assessedvolume ,200 mL/day), while a minority (N 5 6) of
by simple linear and multiple regression analysis. ForCAPD patients had a 24-hour diuresis .500 mL/day.
regression analysis, we used the natural logarithm (ln)HD patients were being treated three times weekly with
of ANP and BNP to normalize the distribution of theirstandard bicarbonate dialysis (Na 138 mmol/L, HCO3 35
plasma concentrations.mmol/L, K 1.5 mmol/L, Ca 1.25 mmol/L, Mg 0.75
The usefulness of natriuretic peptides to identify LVHmmol/L) or by high-flux HD with either cuprophan or
(as previously defined) and systolic dysfunction wassemisynthetic membranes (dialysis filters surface area:
tested by the analysis of receiver operating characteristic1.1 to 1.7 m2). Patients on CAPD were all on four ex-
(ROC) curves [16] and their diagnostic value was com-changes per day schedule with standard dialysis bags.
pared by applying the Wilcoxon rank sum statistics toDry weight was targeted in each case to achieve a normo-
the areas under the ROC curves [17]. The confidencetensive edema-free state. Ninety-nine patients were ha-
bitual smokers (21 6 16 cigarettes per day). intervals of sensitivity, specificity, and positive and nega-
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Table 2. Left ventricular (LV) mass and function and natriureticTable 1. Demographic, anthropometric, biochemical, and
hemodynamic characteristics of the study population peptides in dialysis patients and natriuretic peptides in normal subjects
PatientsAge years 60.2615.3
Males/females 138/108 LV mass index g/height 2.7 64.4619.8
LVEF % 58.169.9BMI kg/m2 24.964.4
Duration of dialysis treatment months 43(18–99) ANP pmol/L median 23.7 (15.8–44.9)
BNP pmol/L median 24.4 (10.4–48.2)Systolic pressure mm Hg 133.9622.4
Diastolic pressure mm Hg 75.3612.3 Normal subjects
ANP pmol/L median 4.5 (2.8–14.0)Heart rate beats/min 80.9610.8
Serum cholesterol mmol/L 5.361.4 BNP pmol/L median 2.4 (1.2–4.0)
Serum phosphate mmol/L 2.060.5 Data are expressed as mean 6 SD or as median (interquartile range), as appro-
Serum calcium mmol/L 2.360.03 priate. Abbreviations are: EF, ejection fraction; ANP, atrial natriuretic peptide;
Serum PTHi pg/mL 147(60–331) BNP, brain natriuretic peptide.
Kt/V
HD patients 1.2260.27
CAPD patients 1.6660.32
History
Myocardial infarction 30 There were highly significant linear associations between
Stroke 20 each peptide and the thickness of the posterior wall
Peripheral vascular disease 31
(ANP, r 5 0.44, P , 0.0001; BNP, r 5 0.50, P , 0.0001)Drug therapy
Erythropoietin 130 and of the interventricular septum wall (ANP, r 5 0.42,
Antihypertensive drugs P , 0.0001; BNP r 5 0.47, P , 0.0001), while the correla-
Monotherapy
tions with the LV end-diastolic volume were of smallACE inhibitors 9
Calcium channel blockers 46 magnitude and borderline significance (ANP, r 5 0.13,
b blockers 7 P 5 0.04; BNP, r 5 0.12, P 5 0.06). Notably, both LVMI
Clonidine or AT1 antagonist or a blockers 14 (Fig. 1) and EF (Fig. 2) were strongly related to ANPDouble or triple therapy (combination of
ACE inhibitors, Calcium channel blockers, and BNP, and these relationships were largely indepen-
AT1 antagonist a or b blockers) 33 dent of other well established determinants of LVMI in
Data are expressed as mean 6 SD or as median (interquartile range), as appro- dialysis patients because they also hold true (P , 0.0001)
priate. Abbreviations are: BMI, body mass index; PTHi, parathyroid hormone
in multivariate models, including age, hemoglobin, serumimmune reactive; Kt/V, dialysis dose; HD, hemodialysis; CAPD, continuous
ambulatory peritoneal dialysis; ACE, angiotensin-converting enzyme; AT1, an- albumin, systolic pressure, Kt/V, treatment modality, and
giotensin II type 1.
duration of dialysis treatment (Figs. 1 and 2, insets). The
correlations between echocardiographic parameters and
BNP were slightly but coherently stronger than those of
tive prediction values were calculated by a standard for- ANP. Natriuretic peptides were also related with the LV
mula [18]. We tested the value of two thresholds (for end-diastolic volume, but again, these relationships were
each peptide). The first threshold was prospectively de- of relatively small magnitude and some of them of bor-
fined and coincided with the 95th percentile of the nor- derline statistical significance.
mal range (discussed previously in this article). The sec-
ond threshold was defined retrospectively on the basis ROC analysis
of the analysis of the ROC curves by identifying the
The areas under the ROC curves of ANP and BNPvalue of each peptide giving the best combination of
were both highly significant (P , 0.001; Fig. 3). Thesensitivity and specificity or “best cut-off,” that is, the
areas for BNP detecting abnormal LVMI and EF werevalue that maximizes the sum of the sensitivity and speci-
slightly larger than those for ANP. This finding suggestsficity [16].
that BNP combined higher sensitivity and higher speci-
ficity over a range of different cut-off values than ANP.
RESULTS Table 3 shows the sensitivity, specificity, and positive
Patient characteristics and negative predictive value of an elevated value of
each peptide as prospectively defined (.95th percentileThe main demographic and clinical characteristics of
of the normal range; Methods section) for the identifica-the patients included in the study are detailed in Table 1.
tion of LVH and systolic dysfunction. BNP had a signifi-Table 2 reports LV mass, LV function, and natriuretic
cantly higher sensitivity (P , 0.0001) than ANP for thepeptides in the patient population and the natriuretic
diagnosis of LVH, but the positive predictive value ofpeptides in the control population. One hundred ninety-
the two peptides was very similar (P 5 NS, 92 and 87%,four (79%) patients displayed LVH on echocardiogra-
respectively). However, the negative predictive value ofphy. Systolic dysfunction was present in 31 patients (13%).
BNP for excluding LVH was 22% higher than that of
Correlation study ANP (P 5 0.05). Both natriuretic peptides had a high
sensitivity for the detection of LV dysfunction (87 andThe plasma concentrations of the two natriuretic pep-
tides were highly intercorrelated (r 5 0.81, P , 0.0001). 94%), but their positive predictive value was low (25 and
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Fig. 1. Relationship between atrial natriuretic peptide (ANP; A) and brain natriuretic peptide (BNP; B) with left ventricular mass indexed to
height (LVMI). Data are expressed as the Pearson product moment correlation coefficient and the relative P value. The corresponding multivariable
models are reported in the insets. ***P , 0.0001; **P , 0.01; *P , 0.05.
15%). Importantly, both ANP and BNP proved to be diagnosis of LVH and for excluding the presence of LV
dysfunction.very useful for excluding this alteration (negative pre-
Left ventricular hypertrophy and LV dysfunction aredictive value 97 and 96%, respectively). Table 4 shows
currently considered the strongest predictors of cardio-the analysis based on the “best cut-offs” of each peptide
vascular and total mortality in the dialysis populationas identified by the analysis of the ROC curves. This
[11, 19]. LVH is a notoriously pervasive complication inanalysis augmented the positive prediction value of BNP
end-stage renal disease with a prevalence rate rangingfor the diagnosis of LVH to 95% in comparison with
from 60 to 80%. LV systolic dysfunction is relativelythe prospective analysis. This increase was paralleled by
much less frequent, with its prevalence being approxi-a nonsignificant gain in negative prediction power that
mately 15% [19]. Our study again further confirms in aattained the 61%. By the same token, this approach
large dialysis population the high prevalence of theseraised the BNP-positive prediction value for the identi-
alterations. If these alterations are to be a target forfication of LV dysfunction to 31%, and this increase was
intervention, simple and reliable methods specificallyagain of borderline statistical significance (P 5 0.05).
validated in the dialysis population are needed. Echocar-This type of analysis did not modify the diagnostic poten-
diography is undoubtedly of proven value, and mosttial of ANP (either for LVH or for LV dysfunction).
agree that serial echocardiographic studies in patients
Combined analysis of the two natriuretic peptides entering renal replacement therapy is a better system to
identify and treat alterations in LV mass and functionThe sensitivity, specificity positive, and negative pre-
in these patients. However, hospital-based echocardio-diction value of the combined diagnostic value of the
graphic services are often stretched, and for this reason,two peptides is shown in Tables 3 and 4. This analysis,
in daily clinical practice, this technique is applied muchbased on either the prospectively identified threshold
less often than desirable. The situation is probably simi-(.95th percentile in healthy subjects) or the “best cut-
lar to that of general practice [20]. Echocardiographyoff” (Methods section), did not materially improve either
apart, there are no simple and validated methods tothe detection of LVH or that of LV dysfunction based
clinically diagnose these abnormalities in dialysis pa-on separate analysis of the two peptides.
tients. Echocardiogram, which is a widely available
method, in the general population has a sensitivity that
DISCUSSION may reach at most 40% [21], and its use in dialysis pa-
The measurement of the plasma concentration of car- tients poses additional problems because of the effect of
diac natriuretic peptides, particularly BNP, in uremic dialysis on the QRS complex [22], that is, the main crite-
rion for the diagnosis of LVH by echocardiogram. Thus,patients on chronic dialysis proved to be useful for the
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Fig. 2. Relationship between ANP and BNP with ejection fraction (EF). Data are expressed as the Pearson product moment correlation coefficient
and the relative P value. The corresponding multivariable models are reported in the insets. ***P , 0.0001; **P , 0.01; *P , 0.05.
the opportunity for intervention on LVH and systolic recognized [37] and further confirmed [38] that it is un-
likely that cardiac natriuretic peptides are of use in thisdysfunction is in part limited by the availability of simple,
easily accessible diagnostic tools. respect.
Left ventricular hypertrophy is a potentially importantThe possibility of using cardiac natriuretic peptides
for the diagnosis of LVH and systolic dysfunction was cause of raised natriuretic peptides in dialysis patients
because there is strong evidence that the myocardialprompted by investigations in early 1990s [1–6], which
showed that the measurement of these hormones, partic- synthesis of ANP and BNP is markedly enhanced in
both animal models [7] as well hypertensive subjects withularly BNP [6], has a substantial potential for predicting
anatomical and functional alterations of the left ventri- raised LVM [6]. The relationship between ANP and
BNP and cardiac mass, geometry, and function in dialysiscle. More recently, both ANP (particularly aminotermi-
nal ANP) and BNP have been used in primary care to patients has received only very scanty attention [38, 39].
Nitta et al reported that BNP may be a possible indicatordiagnose left ventricular dysfunction [4, 23–27]. With the
exception of the study by McClure et al [25], there is a of reduced ventricular function in HD patients [39].
More recently Franz, Woloszczuk, and Horl in a detailedconsensus that the measurement of cardiac peptides is
clinically useful and could be a cost-effective method of study of ANP, pro-ANP, and two aminoterminal pro-
ANP fragments noted that both this cardiac hormonescreening for left-ventricular systolic dysfunction in the
general population, especially if its use was targeted to and the parent prohormone were substantially higher
in patients with cardiac dysfunction (congestive heartindividuals at high risk [24].
Cardiac natriuretic peptide levels are very frequently failure or LV dysfunction, significant valvular heart dis-
ease) [38]. In neither of these studies reported the formalraised in dialysis patients. The high plasma concentration
of ANP and BNP in end-stage renal disease is multifacto- diagnostic value (that is, the prediction power for alter-
ations in LV mass and function) of the cardiac peptides.rial and depends on extracellular volume expansion, con-
comitant heart disease [28, 29], and abolished renal clear- However, the high pretest probability of these heart al-
terations in the dialysis population suggests that ANP andance [30, 31]. ANP in these patients is strictly related to
cardiac filling pressure or to atrial volume [32–35], and BNP might be helpful for their identification. The issue
is important in that LVH and left ventricular dysfunctionalthough to a different rate, the plasma concentration
of both cardiac peptides declines after ultrafiltration dial- are modifiable risk factors in dialysis patients [40].
In this study, to our knowledge the largest performedysis treatment [36]. The measurement of ANP was used
to enhance the identification of the “dry weight.” How- thus far, the plasma concentrations of ANP and BNP
were strongly interrelated, a finding in line with previousever, cardiac function represents a major confounder for
the interpretation of prevailing ANP and BNP plasma data by Buckley et al [31]. Notably, we found that both
natriuretic peptides were correlated to a high degreeconcentration in chronic renal failure, and it is now well
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Fig. 3. Receiver operating characteristic (ROC) curves for natriuretic peptide concentrations in predicting abnormal LV mass and EF (Methods
section). (A) Left ventricular hypertrophy; (B) left ventricular dysfunction.
with several echocardiographic parameters, including off.” Given the high intercorrelation of the two peptides,
there was no gain in diagnostic power when they wereLV mass, the thickness of the left ventricular walls, and
the EF. The link with LVMI and EF was particularly used in a combined way. Thus, our data indicate that
the measurement of ANP or, probably better, BNP hasstrong, so that both peptides had a high positive predic-
tion power (.85%) for LVH coupled to substantial neg- diagnostic potential for alterations in LV mass and func-
tion in dialysis patients. The fact that BNP measurementative prediction power for LV systolic dysfunction
(.95%). In general, BNP was a better predictor than is stable in routine tubes containing EDTA and stored
at room temperature for at least six hours makes theANP, particularly in the analysis based on the “best cut-
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Table 3. Percent and 95% CI using the threshold of .95th percentile of the normal range
Sensitivity Specificity Positive predictive value Negative predictive value
% (95% CI)
LVH
Abnormal ANP 51(44–58) 83(73–83) 92(87–97) 31(23–39)
Abnormal BNP 88(83–93) 50(36–64) 87(82–92) 53(39–67)
LV dysfunction
Abnormal ANP 87(75–99) 62(56–68) 25(17–33) 97(94–100)
Abnormal BNP 94(86–100) 22(16–28) 15(10–20) 96(91–100)
LVH
Abnormal ANP or BNP 89(85–93) 50(36–64) 87(82–92) 54(40–68)
LV dysfunction
Abnormal ANP or BNP 93(86–100) 21(16–28) 15(10–20) 96(90–100)
Table 4. Percent and 95% CI using the threshold of best cut-off values
Positive Negative
Sensitivity Specificity predictive value predictive value
Best cut-off
pmol/L % (95% CI)
LVH
Abnormal ANP 18.8 75(69–81) 75(63–87) 92(88–96) 44(34–54)
Abnormal BNP 23.4 62(55–69) 88(79–97) 95(91–99) 61(52–70)
LV dysfunction
Abnormal ANP 27.1 87(75–99) 62(56–68) 25(17–33) 97(94–100)
Abnormal BNP 38.9 74(59–89) 76(70–82) 31(20–42) 95(92–99)
LVH
Abnormal ANP or BNP 80(74–86) 75(63–87) 92(88–96) 50(39–61)
LV dysfunction
Abnormal ANP or BNP 87(75–99) 61(54–68) 24(16–32) 96(93–99)
The best cut-off threshold values are defined as those values which maximize the sum of the sensitivity and specificity (see Methods).
measurement of this substance feasible in daily clinical peptides, and it remains to be seen whether this affects
practice [41]. Given the high negative prediction power the diagnostic power of ANP and BNP. Nonetheless, it
for systolic dysfunction (96% in the prospective study), is common practice in many dialysis centers to periodi-
the measurement of BNP could be reliably applied to cally re-examine patients in the dialysis interval, and this
exclude this alteration in dialysis patients. Although the may be a good occasion for ANP or BNP testing. Finally,
positive prediction power of this peptide for LVH is high although we analyzed data both on the basis of prospec-
(87% in the prospective study), the negative prediction tively preset thresholds and on retrospectively defined
power is rather unsatisfactory (51%), thus limiting its “best cut offs,” the diagnostic potential of BNP was max-
usefulness for excluding this abnormality. imized by the second, retrospective, approach. Thus,
Our study has limitations. We focused on patients these retrospective thresholds, which are specific for pa-
without overt heart failure because we believed that in tients on dialysis, remain to be prospectively tested in
overt heart failure echocardiography is almost always other dialysis centers to prove the external validity of
performed to confirm the clinical diagnosis and to incor- our findings.
porate anatomic and hemodynamic information into the
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